

CLAIMS PENDING IN APPLICATION FOLLOWING ENTRY OF AMENDMENT

1. (Twice amended) A mucosal adjuvant composition that enhances the effect of medicinal substances administered onto mucosal surfaces, the mucosal adjuvant composition comprising a branched beta-1,3-glucan that contains beta-1,3-linked side chains anchored by a beta-1,6-linkage to the beta-1,3-linked chains.
2. The composition of claim 1 wherein the substance is a vaccine formulation.
3. The composition of claim 1 wherein the substance is an influenza virus vaccine.
4. The composition of claim 1 wherein the substance is administrated into the nasal cavity.
5. The composition of claim 1 wherein the substance is administrated orally.
6. (Amended) The composition of claim 1 wherein the substance is mixed with the mucosal adjuvant composition.
7. (Amended) The composition of claim 1 wherein the substance is administrated prior to the mucosal adjuvant composition.
8. (Amended) The composition of claim 1 wherein the substance and the mucosal adjuvant composition are intended for administration as a nasal spray.
14. The composition of claim 1 wherein the substance is administrated simultaneously with the mucosal adjuvant composition.
15. The composition of claim 1 wherein the substance is administrated after administration of the mucosal adjuvant composition.
16. The composition of claim 1 wherein the substance and the mucosal adjuvant composition are intended for administration as a nasal drops.

17. A mucosal adjuvant composition that enhances the effect of an influenza virus vaccine administered onto mucosal surfaces, the mucosal adjuvant composition comprising glucose monomers linked together in branched beta-1,3 linked chains with beta-1,3,6 linked branching points comprising beta-1,3 linked or beta 1,6 linked side chains.

18. The composition of claim 17 wherein the influenza virus vaccine is administered into the nasal cavity.

19. The composition of claim 17 wherein the influenza virus vaccine is administered orally.

20. The composition of claim 17 wherein the influenza virus vaccine is mixed with the mucosal adjuvant preparation.

21. The composition of claim 17 wherein the influenza virus vaccine is administered prior to the mucosal adjuvant composition.

22. The composition of claim 17 wherein the influenza virus vaccine is administered simultaneously with the mucosal adjuvant composition.

23. The composition of claim 17 wherein the influenza virus vaccine is administered after administration of the mucosal adjuvant composition.


24. The composition of claim 17 wherein the influenza virus vaccine and the mucosal adjuvant composition are intended for administration as a nasal spray.

25. The composition of claim 17 wherein the influenza virus vaccine and the mucosal adjuvant composition are intended for administration as a nasal drops.

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service by Express Mail No. EK944299163US in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on August 20, 2001.

Signed: _____

A handwritten signature in cursive script, appearing to read "Devin O'Quinn", written over a horizontal line.